Objective The purpose of this study, which focuses on the number of the Cochrane Systematic Review’s (CSR) full texts, protocols and registered titles from Chinese authors, is to show the development of evidence-based medicine (EBM) and promote EBM’s further development in China. Methods On the basis of The Cochrane Library (Issue 1, 2009) and the Cochrane Collaboration (March 2009) periodicals, we performed statistical analysis of different countries that released CSR’s full texts, protocols and registered titles, as well as the time, authors and distribution of the CSR’s full texts, protocols and registered titles in China. Results The publishing rates of the CSR’s full texts, protocols and registered titles in China ranked the seventh, fifth and second, respectively. Although the number of CSR’s full texts and protocols showed an increased annual trend in China, the development of area distribution was unbalanced. Moreover, China’s published articles contained 47 Cochrane collaboration groups, without effective practice and health care groups, consumers and communication groups, and methodology and multiple stenosis groups. Conclusions The current Chinese EBM situation has a great potential in writing CSR. However, there are still many problems that need to be resolved.
提高医疗服务质量、确保病人安全是当前医学教育及培训面临的巨大挑战。今天的医生及医务工作者 应具备良好的沟通能力,掌握如何在临床实践中鉴别、预防和处理不良事件及接近过失事件(near misses),如何使 用当前获得的证据及相关信息,如何安全有效地在团队中工作,如何在实践中教授和学习病人安全知识,如何根据 认可的伦理原则服务公众。
Objective To investigate the current situation of clinical studies on puerarin for angina pectoris and assess whether it is adequate to provide evidence for clinical practiice. Methods We collected all the published clinical studies on puerarin for angina pectoris from 1966 to October 2003, and assessed all the included reports according to international clinical epidemiological standard. Results 106 RCTs, 8 non-randomized controlled studies and 24 case series were included and analyzed. 126 studies reported diagnosis criteria, 10 desccribed inclusion criteria; 3 studies were quasi-random, 1 double blind, 4 single blind; no study reported follow-up; 117 studies reported adverse effects. Conclusions Currently the quality of studies on puerarin for angina pectoris is not good enough to provide reliable evidence for clinical practice.
1992年,循证医学(evidence-based medicine,EBM)倡导者提出新"范式",即卫生研究证据是对个体病人及卫生系统决策的最好基础.该方法原意是拟除去传统医学知识体系仅关注疾病本身的病理生理过程及临床经验的积累,因此在2001年被lt;纽约时代杂志gt;评为最具影响力的理论之一.本文回顾了循证医学的产生、发展、哲学局限性和临床实践的挑战.指出EBM的演变、发展早已超出它原来(误解的)概念,即EBM有可能替代传统医学.EBM现正力求去增强而不是替代个人的临床经验及了解疾病的机制.并且EBM一定要继续发展、并探讨一系列的问题包括加强科学基础,伦理道德的重要性及其有关传播及应用的实际事务.例如,为了促进科学研究成果用于临床,证据往往都是从经选择过的人群的不完整证据而来,这些人群仅能从那些贵重技术中得到一些边缘性的好处.而证据的应用就会把这些有限的好处普遍化,由此引发出一系列问题即有多少人和谁能用得起这些新的疗法.因此循证医学的倡导者希望医生及用户关注那些来自临床研究、有效且适于临床应用的好证据.而要达到此目标还需做很多的工作.